• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Denosumab for management of refractory hypercalcaemia in recurrent parathyroid carcinoma.

作者信息

Nadarasa K, Theodoraki A, Kurzawinski T R, Carpenter R, Bull J, Chung T T, Drake W M

机构信息

Department of EndocrinologySt Bartholomew's Hospital, London, UKDepartment of Diabetes and EndocrinologyUCLH NHS Foundation Trust, London, UKDepartment of Endocrine SurgeryUCLH NHS Foundation Trust, London, UKDepartment of NeurosurgeryThe Royal London Hospital, London, UK.

Department of EndocrinologySt Bartholomew's Hospital, London, UKDepartment of Diabetes and EndocrinologyUCLH NHS Foundation Trust, London, UKDepartment of Endocrine SurgeryUCLH NHS Foundation Trust, London, UKDepartment of NeurosurgeryThe Royal London Hospital, London, UK

出版信息

Eur J Endocrinol. 2014 Sep;171(3):L7-8. doi: 10.1530/EJE-14-0482. Epub 2014 Jun 17.

DOI:10.1530/EJE-14-0482
PMID:24939719
Abstract
摘要

相似文献

1
Denosumab for management of refractory hypercalcaemia in recurrent parathyroid carcinoma.地诺单抗用于复发性甲状旁腺癌难治性高钙血症的治疗
Eur J Endocrinol. 2014 Sep;171(3):L7-8. doi: 10.1530/EJE-14-0482. Epub 2014 Jun 17.
2
Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab.继发于甲状旁腺癌的难治性高钙血症：对高剂量地舒单抗的反应。
Eur J Endocrinol. 2014 Jul;171(1):K1-5. doi: 10.1530/EJE-14-0166. Epub 2014 Apr 17.
3
Use of denosumab in parathyroid carcinoma with refractory hypercalcemia.地诺单抗在难治性高钙血症甲状旁腺癌中的应用。
QJM. 2015 Jan;108(1):49-50. doi: 10.1093/qjmed/hcu166. Epub 2014 Aug 6.
4
Is denosumab a long-term option for the treatment of parathyroid carcinoma?地诺单抗是治疗甲状旁腺癌的长期选择吗？
QJM. 2016 Apr;109(4):288. doi: 10.1093/qjmed/hcw013. Epub 2016 Jan 23.
5
Response to "Is denosumab a long-term option for the treatment of parathyroid carcinoma?".对《地诺单抗是治疗甲状旁腺癌的长期选择吗？》的回应
QJM. 2016 Apr;109(4):289. doi: 10.1093/qjmed/hcw019. Epub 2016 Jan 23.
6
Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.地诺单抗对控制恶性肿瘤综合征所致体液性高钙血症患者的血清钙水平有效：一例产生甲状旁腺激素相关蛋白的胆管癌病例报告
Intern Med. 2016;55(23):3453-3457. doi: 10.2169/internalmedicine.55.7134. Epub 2016 Dec 1.
7
Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour.因分泌甲状旁腺激素相关蛋白（PTHrP）的神经内分泌肿瘤导致的恶性肿瘤体液性高钙血症患者，单次注射地诺单抗后出现持续性低钙血症。
Clin Endocrinol (Oxf). 2014 Dec;81(6):940-2. doi: 10.1111/cen.12519. Epub 2014 Jul 2.
8
Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia.
QJM. 2017 Jan;110(1):53-54. doi: 10.1093/qjmed/hcw206. Epub 2016 Dec 22.
9
Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.地诺单抗应是恶性肿瘤双膦酸盐难治性高钙血症的首选治疗药物。
BMJ Case Rep. 2014 Jan 30;2014:bcr2013202861. doi: 10.1136/bcr-2013-202861.
10
Resistant hypercalcaemia in metastatic parathyroid carcinoma.转移性甲状旁腺癌中的难治性高钙血症
Med J Aust. 2013 Jun 3;198(10):559-61. doi: 10.5694/mja12.11243.

引用本文的文献

1
Recurrent parathyromatosis in a patient with concomitant MEN1 and CASR gene alterations: Clinical management of a case report and literature review.伴有 MEN1 和 CASR 基因突变的患者复发性甲状旁腺腺瘤：1 例病例报告及文献复习的临床处理。
Front Endocrinol (Lausanne). 2023 Mar 14;14:1108278. doi: 10.3389/fendo.2023.1108278. eCollection 2023.
2
Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report.地舒单抗治疗甲状旁腺癌高钙血症 1 例报告
Front Endocrinol (Lausanne). 2022 Jan 31;12:794988. doi: 10.3389/fendo.2021.794988. eCollection 2021.
3
Severe symptomatic hyperparathyroidism-Is it carcinoma?-Case report and literature review.
严重症状性甲状旁腺功能亢进——是癌吗？——病例报告及文献综述
Clin Case Rep. 2020 Jun 22;8(8):1476-1482. doi: 10.1002/ccr3.2886. eCollection 2020 Aug.
4
Pitfalls of using denosumab preoperatively to treat refractory severe hypercalcaemia.使用地舒单抗术前治疗难治性重度高钙血症的陷阱。
BMJ Case Rep. 2020 Apr 28;13(4):e233665. doi: 10.1136/bcr-2019-233665.
5
Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.内分泌疾病的管理：继发性骨质疏松症：病理生理学与管理
Eur J Endocrinol. 2015 Sep;173(3):R131-51. doi: 10.1530/EJE-15-0118. Epub 2015 May 13.